Opthea stock reports AUD 330.4 million profit after reset
Published on 09/30/2026 at 18:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Opthea stock is tied to a sharp corporate reset after the company now known as Ceryvyn Therapeutics reported AUD 330.4 million in fiscal 2026 profit. The result followed the settlement and derecognition of its Development Funding Agreement, which created a AUD 357.1 million accounting gain, according to Quartr on August 31, 2026.
Profit follows the DFA settlement
The FY26 profit contrasts with a AUD 251.1 million loss in FY25, giving the headline result a restructuring-driven character rather than the profile of recurring operating earnings. Cash and cash equivalents stood at AUD 30.0 million at June 30, 2026, down from AUD 73.9 million a year earlier, according to Quartr.
That comparison matters for investors because the AUD 330.4 million profit and the AUD 357.1 million gain point to balance-sheet repair as the central financial event of fiscal 2026. The cash balance provides the operating base for the next development phase.
New name, narrower pipeline
Reuters describes Ceryvyn Therapeutics as the former Opthea Limited and identifies its lead program as CYV-101, a fusion protein designed to neutralize VEGF-C and VEGF-D in lymphangioleiomyomatosis, a rare progressive lung disease. The company's industry classification is biotechnology, and its strategic direction now centers on rare disease development, according to Reuters.
Ceryvyn's September 21, 2026 corporate presentation described cash reserves of AUD 37.6 million, including a AUD 10.8 million research and development tax incentive, while the company evaluates a staged LAM program, according to Quartr. The difference between that presentation figure and the June 30 cash figure reflects the reporting dates and subsequent funding item.
ASX valuation remains small
Ceryvyn traded at AUD 0.01 on the ASX on September 29, 2026, based on a quoted value of AUD 0.009, while its market capitalization was AUD 12.0 million, according to InvestSMART. The same page lists November 18, 2026, as the date of the annual general meeting.
The capital structure remains an important counterweight to the strategic reset. A September 8 announcement covered a proposed issue of 3,000,000 options with an exercise price of AUD 0.01 and expiry on September 21, 2031, according to TipRanks. That proposal adds a potential dilution consideration as the company funds its clinical strategy.
Opthea stock and the new identity
Opthea stock now represents a company operating under the Ceryvyn Therapeutics name and ticker CYV. The investment case has therefore shifted from the former ophthalmology pipeline toward CYV-101 and a rare-disease program supported by the post-settlement balance sheet.
Ceryvyn Therapeutics market facts
- Company: Ceryvyn Therapeutics Limited
- Ticker: CYV
- Primary exchange: ASX
- ASX price on September 29, 2026: AUD 0.01
- Market capitalization on September 29, 2026: AUD 12.0 million
- Sector / Industry: Healthcare / Biotechnology
